BLIS Technologies Limited (NZE:BLT)

Market Cap	20.47M +6.7%
Revenue (ttm)	14.35M +12.3%
Net Income	1.03M -33.5%
EPS	0.00 -44.0%
Shares Out	1.28B
PE Ratio	21.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126,116
Average Volume	177,578
Open	0.0160
Previous Close	0.0160
Day's Range	0.0160 - 0.0160
52-Week Range	0.0130 - 0.0220
Beta	0.39
RSI	36.84
Earnings Date	Feb 26, 2026

About BLIS Technologies

BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand, Asia Pacific, Europe Middle East and Africa, and North America. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 38
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: BLT

Financial Performance

In fiscal year 2025, BLIS Technologies's revenue was 12.67 million, an increase of 9.49% compared to the previous year's 11.57 million. Earnings were 838,000, an increase of 29.72%.